Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
OpenAI Rejects Apple Trade Secret Theft Claims 
Trump Says ExxonMobil Among Oil Majors Planning Venezuela Return 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
France Targets Shein, Temu With Fast-Fashion Fees 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
OpenAI Nears Astra AI Model Launch With Safety Focus 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
South Korea Unveils Record $597 Billion 2027 Budget to Boost AI and Chips 
Shein Shares Slide 9% in Hong Kong IPO Debut 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Apple’s Phil Schiller Steps Back as Leadership Shake-Up Accelerates 
Add as a preferred source on Google
NEW HAVEN, Conn., March 14, 2018 -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, announced today that Dan Wechsler, President and CEO of Melinta, will be presenting at Needham & Company’s 17th Annual Healthcare Conference in New York, NY. Mr. Wechsler’s presentation will take place on Tuesday, March 27, 2018 at 12:45pm Eastern Time. A live and archived webcast of the presentation will be accessible from the Melinta Events & Presentations section of the Investors webpage.
Needham & Company’s Annual Healthcare Conference is host to over 130 public and private companies across the life sciences sectors. It is taking place March 27-28, 2018 at the Westin Grand Central Hotel in New York, NY.
About Melinta Therapeutics
Melinta Therapeutics, Inc. is the largest pure-play antibiotics company, dedicated to saving lives threatened by the global public health crisis of bacterial infections through the development and commercialization of novel antibiotics that provide new and better therapeutic solutions. Its four marketed products include Baxdela™ (delafloxacin), Vabomere™ (meropenem and vaborbactam), Orbactiv® (oritavancin), and Minocin® (minocycline) for Injection. It also has an extensive pipeline of preclinical and clinical-stage products representing many important classes of antibiotics, each targeted at a different segment of the anti-infective market. Together, this portfolio provides Melinta with the unique ability to provide providers and patients with a range of solutions that can meet the tremendous need for novel antibiotics treating serious infections. Visit www.melinta.com for more information.
For More Information:
Media Inquiries:
Amra Maynard
(917) 302-2702
[email protected]
Investor Inquiries:
Lisa DeFrancesco
(847) 681-3217
[email protected]
Raj Mistry
(312) 801-2051
[email protected]
